The following is a summary of the PetVivo Holdings, Inc. (PETV) Q2 2025 Earnings Call Transcript:
Financial Performance:
PetVivo reported a sequential revenue growth of 62% in the fiscal second quarter, primarily driven by a 147% increase in distributor sales.
The company achieved a gross profit margin of 89.5%.
Net loss improved significantly from $3.7 million last year to $2.2 million this quarter.Operating expenses declined by 25% due to strategic company-wide reduction and restructuring programs.
Business Progress:
PetVivo expanded the distribution of its flagship product, Spryng, which has now reached over 800 clinics across all 50 states.
New clinical trials, including an elbow study for dogs with osteoarthritis, are underway, enhancing the product's validation and adoption.
Significant staffing increases in sales and marketing roles have been made to support growth, especially aimed at the companion animal market.
PetVivo participated in major veterinary conferences and events, boosting visibility and advocacy for its Spryng product among veterinary professionals.
Opportunities:
The expansion into the companion animal market, a significantly larger market segment, aims at driving future revenue growth.
Continued collaboration with leading R&D companies, like Orthobiologic Innovations, for product development and clinical trials to enhance product adoption.
Risks:
Transition from smaller equine markets to companion animal markets involves risk of market acceptance and operational adjustments.
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
